How to Choose Between CJC-1295 and Other Peptides
A clear guide to how CJC-1295 compares with the other options people consider, including sermorelin, tesamorelin, ipamorelin and growth hormone itself, and a practical framework for choosing with your prescriber.
- CJC-1295, sermorelin and tesamorelin act on the GHRH receptor; ipamorelin acts on a different pathway.
- Only tesamorelin and recombinant growth hormone are currently FDA approved, each for specific conditions.
- CJC-1295 has the longest action of the GHRH analogs but the thinnest regulatory history.
- Results from tesamorelin or growth hormone should not be borrowed as evidence for CJC-1295.
- Start with your goal, your health history and what the evidence actually shows.
- For some goals, treating an underlying cause or lifestyle changes will help more than any peptide.
In this article
CJC-1295 is one of several options people consider when they are interested in growth hormone related treatment. Comparing them can be confusing, because marketing often blurs the differences and borrows evidence from one medicine to promote another. This guide sets out how the main options differ, what the evidence for each actually covers, and a practical way to choose with your prescriber. For a deeper look at CJC-1295 itself, see our guide to what CJC-1295 is.
CJC-1295 is not approved by the FDA for any use. It is prescribed at a licensed physician's discretion after a medical review. This article is educational and is not medical advice.
Two Different Pathways
Your pituitary gland releases growth hormone in response to two main signals. Growth hormone releasing hormone (GHRH) is one. Ghrelin, a hormone better known for its role in hunger, is the other, acting through a separate receptor. Medicines in this space work through one of these pathways, or replace growth hormone directly.
- GHRH analogs: CJC-1295, sermorelin and tesamorelin. They bind the GHRH receptor.
- Ghrelin receptor agonists: often called growth hormone secretagogues, such as ipamorelin.
- Growth hormone itself: recombinant human growth hormone, which bypasses the pituitary entirely.
The Options at a Glance
| Option | What it is | How it works | FDA status | Strength of human evidence |
|---|---|---|---|---|
| CJC-1295 with DAC | Long acting GHRH analog | Binds the GHRH receptor; lasts days | Never approved | Small pharmacology studies in healthy adults |
| Sermorelin | Short GHRH analog | Binds the GHRH receptor; cleared within minutes | Approved in 1997 for children; later withdrawn for non safety reasons | Pediatric approval data and older adult studies |
| Tesamorelin | Stabilised GHRH analog | Binds the GHRH receptor | Approved for HIV associated abdominal fat | Large randomised trials in that specific group |
| Ipamorelin | Growth hormone secretagogue | Acts on the ghrelin receptor, a different pathway | Never approved | Mainly animal and early human research |
| Recombinant growth hormone | Growth hormone itself | Replaces growth hormone directly | Approved for diagnosed deficiency and specific conditions | Extensive, for approved uses |
CJC-1295
CJC-1295 with DAC is a modified GHRH analog that binds albumin in the blood, so it lasts days rather than minutes. In healthy adults, a single injection raised growth hormone for six days or more and IGF-1 for nine to eleven days, with an estimated half life of 5.8 to 8.1 days. Its strengths are infrequent dosing and preserved natural growth hormone pulses in research. Its weaknesses are a small evidence base, no approval, a Phase II trial halted in 2006 after a participant died, and an FDA report of serious adverse events including increased heart rate and systemic vasodilatory reaction. Our review of CJC-1295 clinical studies sets out the full evidence.
Sermorelin
Sermorelin is the first 29 amino acids of natural GHRH. It is cleared within minutes, so it is usually injected daily. It was approved by the FDA as Geref in 1997 for children with growth hormone deficiency and later discontinued; in 2013 the FDA determined it was not withdrawn from sale for reasons of safety or effectiveness. For adults it is prescribed off label. Its short action means effects fade quickly if treatment is stopped. Our CJC-1295 vs sermorelin guide compares the two in depth.
Frequently Asked Questions
What is the difference between CJC-1295 and ipamorelin?
CJC-1295 acts on the GHRH receptor and, with DAC, lasts days. Ipamorelin acts on the ghrelin receptor, a separate pathway. Neither is FDA approved.
Is tesamorelin the same as CJC-1295?
No. Both are GHRH analogs, but tesamorelin is a different molecule that completed large trials and is approved for HIV associated abdominal fat. Its results should not be applied to CJC-1295.
Which growth hormone peptides are FDA approved?
Tesamorelin is approved for HIV associated abdominal fat. Sermorelin was approved for children in 1997 but later discontinued. CJC-1295 and ipamorelin have never been approved.
Should I take growth hormone instead of a peptide?
Recombinant growth hormone is approved for diagnosed deficiency and specific conditions and is managed by specialists. If you have symptoms of a true deficiency, see an endocrinologist.
How do I choose the right option?
Start with a specific goal, check what each option's evidence actually measured, review your health history, weigh practicalities such as injection frequency, and agree a monitoring plan with your prescriber.
Can athletes use any of these peptides?
Not in tested sport. Growth hormone releasing factors and secretagogues are prohibited at all times under the World Anti-Doping Agency code.
Tesamorelin
Tesamorelin is a stabilised GHRH analog that completed full clinical development. In a large randomised trial in people with HIV and excess abdominal fat, it reduced visceral fat compared with placebo, and it was later approved by the FDA for that specific condition. It is often cited in discussions of CJC-1295, but its results come from a different molecule, a different population and a different dosing schedule. They should not be treated as evidence that CJC-1295 has the same effect.
Ipamorelin
Ipamorelin acts on the ghrelin receptor rather than the GHRH receptor. It was described in early research as the first selective growth hormone secretagogue, meaning it released growth hormone without large effects on certain other hormones in animal studies. It has not been approved. The FDA has placed it in a category of substances that may present significant safety risks for some compounding, noting reports of serious adverse events including death when ipamorelin was given intravenously in a study of gastric motility. It is often combined with CJC-1295; our article on combining CJC-1295 with other peptides covers what is and is not known about that.
Recombinant Growth Hormone
Recombinant human growth hormone replaces growth hormone directly. It is approved for diagnosed growth hormone deficiency and certain other conditions, and is prescribed and monitored by specialists. It bypasses the pituitary's own feedback controls, which is one reason it is reserved for clear medical need. If you have symptoms suggesting a true deficiency, the right step is an endocrinology assessment rather than a peptide.
Why Evidence Does Not Transfer Between Peptides
It is tempting to assume that peptides acting on the same receptor will have the same effects. They do not, necessarily. Small changes in structure alter how long a peptide lasts, how strongly it binds, how it is broken down and what side effects it causes. A medicine's trial results also depend on who was studied, at what dose and for how long. That is why tesamorelin's results in people with HIV associated abdominal fat, or growth hormone's results in diagnosed deficiency, cannot be used to predict what CJC-1295 or ipamorelin will do in healthy adults. Each option should be judged on its own evidence.
A Practical Framework for Choosing
1. Start with your goal. Be specific. Is it better sleep, more energy, recovery, body composition or a diagnosed deficiency? Then ask what the evidence for each option actually measured. For CJC-1295, the human research measured hormone levels, not those outcomes. Writing your goal down, along with how you will measure it, makes the later review with your prescriber far more useful.
2. Check your health history. Active cancer, pregnancy and breastfeeding rule out all of these options outside specialist care. Heart disease, diabetes and pituitary conditions need careful review. Competitive athletes should avoid growth hormone releasing peptides entirely, as they are prohibited at all times under the World Anti-Doping Agency code. See our guide on who should not use CJC-1295.
3. Weigh evidence and regulatory status. Approved medicines have been through full trials for their approved uses. Unapproved peptides have not, and the gap in safety data is real.
4. Consider practicalities. Daily versus infrequent injections, the ability to stop quickly, cost over several months, storage and travel.
5. Plan monitoring. Whatever you choose, agree which labs will be checked, when, and what result would change the plan.
What About Combining Options?
CJC-1295 is often marketed in combination with ipamorelin, on the idea that acting on two pathways together produces a bigger growth hormone release. There are no published clinical trials of the combination for health outcomes, and combining treatments makes IGF-1 harder to predict and side effects harder to attribute. If a combination is ever considered, it should be a deliberate choice by your prescriber with closer monitoring, not a default package.
Monitoring, Whatever You Choose
All of these options are monitored in broadly the same way: IGF-1 before treatment and at intervals afterwards, kept within a safe range for your age and sex, plus blood sugar and other tests based on your history. A written log of doses, symptoms and your own goals helps your prescriber judge whether the option you chose is working for you.
Questions to Ask Your Prescriber
- Which options are realistic for my goal and my health history?
- What does the evidence for each actually show, and in which group of people?
- Is there an underlying cause we should check first?
- How often would I inject, and how quickly could I stop if needed?
- Which labs will you check, and what would make you change course?
Look for Simpler Answers First
Many of the goals that lead people to peptides have common, treatable causes. Sleep apnea, thyroid problems, low iron, low vitamin D, poor sleep habits, low mood and the side effects of other medicines can all cause tiredness, poor recovery and weight gain. A careful prescriber checks for these first. Our comparison of peptide therapy and lifestyle changes explains why sleep, training and nutrition remain the foundation.
Cost and Access
Costs vary widely between options, pharmacies and providers. Approved medicines such as growth hormone and tesamorelin may be covered by insurance for their approved uses but are expensive otherwise. Compounded peptides such as CJC-1295 and sermorelin are usually paid for out of pocket. Compare the full cost over several months, including consultations, lab tests and supplies, rather than the price of a single vial.
Red Flags When Comparing Options
- Claims that one peptide is proven to build muscle, burn fat or reverse aging in healthy adults.
- Results from tesamorelin or growth hormone presented as evidence for CJC-1295 or ipamorelin.
- Dose packages chosen by goal rather than by a medical assessment.
- Products sold without a prescription, a pharmacy label or a lot number, or labelled for research use only.
- No mention of side effects, monitoring or who should not use the product.
Conclusion
CJC-1295, sermorelin and tesamorelin all act on the GHRH receptor, ipamorelin acts through the ghrelin receptor, and recombinant growth hormone replaces the hormone directly. Only tesamorelin and growth hormone are currently approved, each for specific conditions, and evidence from one should not be borrowed for another. The best choice starts with a clear goal, an honest look at what each option's evidence covers, your health history and practical needs, and a monitoring plan, all agreed with your prescriber. If you would like a physician to help you weigh your options, you can start your online assessment.
In this article
